rivastigmine has been researched along with 3-(1-dimethylaminoethyl)phenol in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (60.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chappuis, A; Dattler, A; Enz, A | 1 |
| Beijnen, JH; Frankfort, SV; Ouwehand, M; Rosing, H; Tulner, LR; van Maanen, MJ | 1 |
| Appel-Dingemanse, S; Enz, A; Ereshefsky, L; Huang, HL; Jhee, SS; Lefèvre, G; Leibowitz, MT; Maton, S; Pommier, F; Schmidli, H; Sedek, G | 1 |
| Allison, M; Appel-Dingemanse, S; Ho, YY; Huang, HL; Kiese, B; Lefèvre, G; Pommier, F; Sedek, G | 1 |
| Athalye, S; Lefèvre, G; Picard, F; Pommier, F; Sedek, G; Shua-Haim, J; Smith, J | 1 |
| Chen, SH; Hsieh, YH; Lin, PC; Yang, YH; Yeh, HH | 1 |
| Abd El-Rahman, MK; El-Bardicy, MG; El-Kosasy, AM; Salem, MY | 1 |
| Ansermot, N; Dobrinas, M; Eap, CB; Noetzli, M | 1 |
| Chen, CH; Chen, SH; Chou, MC; Liu, CK; Wu, SJ; Yang, YH | 1 |
| Chou, PS; Huang, LC; Jhang, KM; Wang, WF; Yang, YH | 1 |
2 trial(s) available for rivastigmine and 3-(1-dimethylaminoethyl)phenol
| Article | Year |
|---|---|
Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients.
Topics: Administration, Cutaneous; Administration, Oral; Aged; Alzheimer Disease; Benzylamines; Butyrylcholinesterase; Capsules; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Models, Biological; Phenethylamines; Phenols; Phenylcarbamates; Rivastigmine; Treatment Outcome | 2008 |
Pharmacokinetics and bioavailability of the novel rivastigmine transdermal patch versus rivastigmine oral solution in healthy elderly subjects.
Topics: Administration, Cutaneous; Administration, Oral; Aged; Area Under Curve; Benzylamines; Biological Availability; Cholinesterase Inhibitors; Chromatography, High Pressure Liquid; Cross-Over Studies; Dizziness; Female; Half-Life; Headache; Humans; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Phenethylamines; Phenols; Phenylcarbamates; Rivastigmine; Sleep Initiation and Maintenance Disorders; Solutions; Tandem Mass Spectrometry; Vomiting | 2008 |
8 other study(ies) available for rivastigmine and 3-(1-dimethylaminoethyl)phenol
| Article | Year |
|---|---|
A simple, rapid and sensitive method for simultaneous determination of rivastigmine and its major metabolite NAP 226-90 in rat brain and plasma by reversed-phase liquid chromatography coupled to electrospray ionization mass spectrometry.
Topics: Animals; Benzylamines; Cholinesterase Inhibitors; Chromatography, Liquid; Phenethylamines; Phenols; Phenylcarbamates; Rats; Reproducibility of Results; Rivastigmine; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization | 2004 |
A simple and sensitive assay for the quantitative analysis of rivastigmine and its metabolite NAP 226-90 in human EDTA plasma using coupled liquid chromatography and tandem mass spectrometry.
Topics: Administration, Oral; Benzylamines; Cholinesterase Inhibitors; Chromatography, High Pressure Liquid; Edetic Acid; Humans; Phenethylamines; Phenols; Phenylcarbamates; Reproducibility of Results; Rivastigmine; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2006 |
Steady-state pharmacokinetics of rivastigmine in patients with mild to moderate Alzheimer's disease not affected by co-administration of memantine: an open-label, crossover, single-centre study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Area Under Curve; Benzylamines; Cholinesterase Inhibitors; Cross-Over Studies; Excitatory Amino Acid Antagonists; Female; Humans; Male; Memantine; Middle Aged; Phenethylamines; Phenols; Phenylcarbamates; Rivastigmine | 2008 |
Simultaneous determination of galantamine, rivastigmine and NAP 226-90 in plasma by MEKC and its application in Alzheimer's disease.
Topics: Adult; Alzheimer Disease; Benzylamines; Buffers; Cholinesterase Inhibitors; Chromatography, Micellar Electrokinetic Capillary; Drug Monitoring; Galantamine; Humans; Male; Phenethylamines; Phenols; Phenylcarbamates; Phosphoric Acids; Reproducibility of Results; Rivastigmine; Sensitivity and Specificity; Solvents; Surface-Active Agents | 2009 |
Spectrophotometric and spectrodensitometric methods for the determination of rivastigmine hydrogen tartrate in presence of its degradation product.
Topics: Benzylamines; Cholinesterase Inhibitors; Chromatography, Thin Layer; Densitometry; Drug Stability; Phenethylamines; Phenols; Phenylcarbamates; Reproducibility of Results; Rivastigmine; Spectrophotometry | 2010 |
Simultaneous determination of antidementia drugs in human plasma: procedure transfer from HPLC-MS to UPLC-MS/MS.
Topics: Chromatography, High Pressure Liquid; Donepezil; Drug Stability; Galantamine; Humans; Indans; Memantine; Nootropic Agents; Phenethylamines; Phenols; Phenylcarbamates; Piperidines; Plasma; Reference Standards; Reproducibility of Results; Rivastigmine; Tandem Mass Spectrometry | 2012 |
Concentrations of rivastigmine and NAP 226-90 and the cognitive response in Taiwanese Alzheimer's disease patients.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cognition Disorders; Female; Follow-Up Studies; Humans; Male; Phenethylamines; Phenols; Phenylcarbamates; Pilot Projects; Rivastigmine; Taiwan | 2012 |
Skinfold thickness for rivastigmine patch application in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Female; Humans; Male; Middle Aged; Phenethylamines; Phenols; Rivastigmine; Skinfold Thickness | 2019 |